The antimalarial drug artesunate (ART) effectively disrupts the interaction between USP7 and BCR-ABL, leading to the degradation of BCR-ABL and ultimately causing the death of CML cells [38]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.